| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer | CFO
2 companies
Schond L. Greenway last filed a Form 4 in March 2024, as Chief Financial Officer at MNMD. The filings on record cover 2 companies. Schond L. Greenway's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 211,057 shares of MNMD. The MNMD filings lean toward selling, a net 43,049 shares.
Schond L. Greenway has 11 Form 4 filings on record from March 2021 to March 2024, across 2 companies: Chief Financial Officer at MNMD, 2022–2024; CFO at Avalo Therapeutics (AVTX), 2021.
The 14 reported transactions were 6 open-market sales, 3 option or other derivative awards, 2 stock awards and 2 open-market purchases, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 2 purchases worth about $5K and 4 sales worth about $154K.
The largest open-market purchase was 2,231 shares of AVTX at an average $1.57 on December 10, 2021, about $4K. Twelve months later AVTX was down 77%.
The largest open-market sale was 20,000 shares of MNMD at an average $3.80 on August 25, 2023, about $76K.
None of the 4 sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
Shares as reported in the last Form 4 for each company; the most recent is from March 2024. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 26, 2023 | Chief Financial Officer | Sell | 5,652 | $3.63 | $20,516.76 | -2.5% | - | - | ||
| Sep 25, 2023 | Chief Financial Officer | Sell | 5,762 | $3.58 | $20,608.88 | -2.5% | - | - | ||
| Aug 25, 2023 | Chief Financial Officer | Sell | 20,000 | $3.80 | $76,000.00 | -8.1% | - | - | ||
| Jun 27, 2023 | Chief Financial Officer | Sell | 11,635 | $3.20 | $37,194.47 | -4.5% | - | - | ||
| Dec 10, 2021 | AVTX Avalo Therapeutics, Inc. | CFO | Buy | 2,231 | $1.57 | $3,502.67 | +135.0% | -61.9% | -76.6% | |
| Jun 10, 2021 | AVTX Avalo Therapeutics, Inc. | CFO | Buy | 652 | $2.68 | $1,747.36 | +65.2% | -22.9% | -87.0% |